Nilotinib-induced liver injury: A case report

INTRODUCTION: Nilotinib is a selective inhibitor of the BCR-ABL tyrosine kinase receptor and is used in the management of chronic myelogenous leukemia (CML). Nilotinib therapy at high doses is associated with elevated serum bilirubin levels. If the serum bilirubin level exceeds 3 times the upper lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Youwen, Ye, Yun, Zhou, Xingbei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478446/
https://www.ncbi.nlm.nih.gov/pubmed/32899072
http://dx.doi.org/10.1097/MD.0000000000022061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478446/
https://www.ncbi.nlm.nih.gov/pubmed/32899072
http://dx.doi.org/10.1097/MD.0000000000022061

Ejemplares similares